[Effect of interferon on the development of Parkinson's syndrome, caused by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in C57Bl/6 mice].
Davydova
G V
GV
Fomina
V G
VG
Kryzhanovskiĭ
G N
GN
Krupina
N A
NA
Pletsityĭ
K D
KD
Kucherianu
V G
VG
D000818:Animals; D015259:Dopamine Agents / Q000633:toxicity*; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D020267:MPTP Poisoning; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000517:prevention & control*; D011994:Recombinant Proteins
D015259:Dopamine Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
Vliianie interferona na razvitie Parkinsonicheskogo sindroma, vyzvannogo vvedeniem 1-metil-4-fenil-1,2,3,6-tetragidropiridina (MFTP), u mysheĭ C57Bl/6.